Abstract
Antibody-drug conjugates (ADC) represent a distinct family of chemoimmunotherapy agents. ADCs are composed of monoclonal antibodies conjugated to cytotoxic payloads via specialized chemical linkers. ADCs therefore combine the immune therapy with targeted chemotherapy. Due to the distinct biomarkers associated with lymphocytes and plasma cells, ADCs have emerged as a promising treatment option for lymphoid malignancies and multiple myeloma. Several ADCs have been approved for clinical applications: brentuximab vedotin, inotuzumab ozogamicin, moxetumomab pasudotox, and polatuzumab vedotin. More novel ADCs are under clinical development. In this article, we summarized the general principles for ADC design, and updated novel ADCs under various stages of clinical trials for lymphoid malignancies and multiple myeloma.
Highlights
Monoclonal antibodies such as rituximab and obinutuzumab are a major component in the combination regimens for the therapy of lymphoid malignancies [1–6]
We discussed the general principles of Antibody-drug conjugates (ADC) design and updated on novel ADCs in clinical trials for the treatment of lymphoid malignancies and multiple myeloma
In an ongoing randomized phase II trial (NCT02257567), Polatuzumab vedotin (Pola) was added to the regimen of bendamustine plus rituximab (BR) or obinutuzumab (BO) for patients with R/R diffuse large B cell lymphoma (DLBCL) or R/R follicular lymphoma (FL) ineligible for autologous stem cell transplantation (ASCT)
Summary
Monoclonal antibodies such as rituximab and obinutuzumab are a major component in the combination regimens for the therapy of lymphoid malignancies [1–6]. A separate phase II trial (NCT00867087) reported only 29% ORR after 3 cycles of R-InO for patients with R/R DLBCL [91].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
